Brazil Approves Legal Medical Cannabis Cultivation and Broadens Patient Eligibility

For the first time in its history, Brazil has legalized the cultivation of medical cannabis, marking a pivotal development for Latin America's most populous country. The new regulations, announced by Brazil's health authorities, permit cannabis to be grown domestically for pharmaceutical and scientific purposes. This change also enables certain patient associations to participate in cultivation, a significant shift from the previous policy that only allowed cannabis products to be imported. The move comes in response to a November 2024 court directive requiring the government to establish a regulatory framework for cannabis growing

The regulations, developed by Anvisa, Brazil’s pharmaceutical regulatory agency, reflect a nuanced approach to cannabis policy. Private companies are now permitted to cultivate cannabis as long as the plants contain no more than 0.3% THC. Additionally, institutions involved in scientific research can grow cannabis without any THC limit, while patient associations will also be able to apply for cultivation permits after a forthcoming official call from Anvisa. "The new allowance is undoubtedly a major advance in Brazil’s national cannabis control policy," attorney Erik Torquato told Brasil de Fato

Previously, Brazilian patients seeking medical cannabis faced significant barriers, as access was limited to those in severe palliative care and required costly imports. Under the expanded guidelines, medical cannabis will now be available to individuals with chronic diseases, greatly increasing the pool of eligible patients. Patient associations, modeled after collectives in the U.S. and Canada, are expected to play a crucial role in cultivating and distributing medical cannabis to those in need. Anvisa's initiative is seen as a response to both legal mandates and increasing demand from patient advocacy groups

While the new policy represents a notable liberalization, cannabis cultivation remains tightly regulated and adult-use cannabis continues to be illegal in Brazil. The Superior Court of Justice had previously ruled that national drug laws do not apply to cannabis varieties with low THC content, paving the way for these recent changes. In addition to domestic cultivation, Brazil will now allow imports of cannabis plant material and oil for pharmaceutical manufacturing, further supporting the medical cannabis industry. These measures are intended to balance patient needs with public health and safety concerns

Industry observers note that Brazil's move could have significant implications for the broader Latin American cannabis market. With over 200 million residents, Brazil's demand for medical cannabis may spur investment, innovation, and regulatory harmonization across the region. According to Courthouse News, the selection and oversight of patient associations by Anvisa will be closely watched, as their success could serve as a model for other emerging markets. The regulatory framework's effectiveness in ensuring quality, safety, and equitable access will be crucial as the market matures

From the OG Lab newsroom perspective, Brazil's decision to legalize medical cannabis cultivation and broaden patient access signals a major shift in both policy and market opportunity. As the country implements these changes, stakeholders should watch for how patient associations navigate the regulatory landscape and how expanded access impacts patient outcomes. This development is poised to reshape the Latin American medical cannabis industry and could inspire similar reforms in other countries facing rising demand for therapeutic cannabis products